StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Up 290.2 %
GLMD stock opened at $15.10 on Friday. Galmed Pharmaceuticals has a 12-month low of $2.73 and a 12-month high of $23.80. The company has a 50 day moving average of $3.83 and a two-hundred day moving average of $4.12. The company has a market cap of $76.18 million, a price-to-earnings ratio of -6.29 and a beta of 0.67.
About Galmed Pharmaceuticals
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- 3 Monster Growth Stocks to Buy Now
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Investing in the High PE Growth Stocks
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- What is Forex and How Does it Work?
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.